SUZHOU, China, Sept. 12, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), has been...
BEIJING, Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today...
XIAMEN, China, Sept. 10, 2025 /PRNewswire/ -- POP Culture Group Co., Ltd. ("Company") (NASDAQ: CPOP) today announced the completion of a major strategic investment...
SHANGHAI, Sept. 10, 2025 /PRNewswire/ -- Jinxin Technology Holding Company (the "Company") (Nasdaq: NAMI), an innovative provider of digital-content products and services in China,...